Magnitude Biosciences secures £1.3m investment
Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. VivoScan is unique in providing HTS for drug discovery in a… Read More